Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Post-transplantation cyclophosphamide-based after HLA-matched versus haploidentical donor transplants in patients with Hodgkin lymphoma: a comparative study of the LWP EBMT

Études rétrospectives

Lymphome non hodgkinien (LNH)

Lymphoma Working Party (LWP)

Type de traitement

Allogénique - Haplo-identique

Investigateur principal

Dr. Juan Montoro

Real life analysis BV use as consolidation therapy in HL with high risk post ASCT

Retrospective Studies

Hodgkin’s Disease (HD)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Mariana Bastos Oreiro

Outcomes of Allogeneic HCT in patients with Hodgkin Lymphoma in the era of Checkpoint Inhibitors: A joint CIBMTR and EBMT analysis.

Retrospective Studies

Hodgkin’s Disease (HD)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Miguel-Angel Perales

Allogeneic Stem Cell TransplantationIn NK/ T-cell lymphoma

Retrospective Studies

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Norbert Schmitz

A comparison between ATG and PT-CY graft-versus-host-disease prophylaxis in patients with lymphoma undergoing reduced intensity conditioning regimen HSCT from 1 antigen MMUD

Retrospective Studies

Lymphoma Working Party (LWP)

Type de traitement

Allogeneic - Unrelated

Investigateur principal

Annalisa Paviglianiti

Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma.

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Steve Robinson / Claire Burney

Stem Cell Transplantation in blastic plasmocytoid dendritic cell neoplasia. A joint NIS with the ALWP

Non-interventional Prospective Studies

Other myeloid or lymphoid malignancies

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Sascha Dietrich, Peter Dreger

Allogeneic Stem Cell Transplantation for cutaneous T-cell lymphoma

Non-interventional Prospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

LYM1: Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Clinical Trials Phase I-III

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Ruth Pettengell

Long Term Outcome of a Second Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Retrospective Analysis from the Lymphoma Working Party of EBMT

Retrospective Studies

Hodgkin’s Disease (HD)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party.

Retrospective Studies

Hodgkin’s Disease (HD)

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal